Diabetic patients who need insulin therapy or oral sulfonylureas and individuals at high cardiovascular risk should be given a treatment plan that minimizes the risk of hypoglycemia and its associated CVD risk factors. The gene discussed is INS; the disease is Hypoglycemia.